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Abstract
Background: Milk protein fractions and peptides have been shown to have bioactive properties. This preliminary
study examined the potential mechanisms of action and clinical safety of novel milk protein peptide (MP).
Findings: A novel MP mixture inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR),
vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR) with IC50 of 9.85 μM, 7.7 μM, and
6.18 μM respectively. In vitro, this multi-kinase inhibitor causes apoptosis in HT-29 colon cancer cells, and in a C.
elegans worm study, showed a weak but significant increase in lifespan. A six week double-blind, placebo-
controlled study involving 73 healthy volunteers demonstrated that the MP mixture is safe to consume orally. All
clinical blood markers remained within normal levels and no clinically significant side effects were reported. There
was some evidence of improved insulin sensitivity, neutrophil-to-lymphocyte ratio (NLR), and quality of life
assessment of role of physical function.
Conclusions: These data in combination with the observed in vitro anti-cancer properties warrant further clinical
studies to investigate this MP mixture as a potential clinical nutrition intervention for improving the quality of life
and clinical outcomes in cancer patients.
Trial Registration: NCT01412658
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Findings
Clinical nutrition products are specifically formulated
nutrients to help people manage various health condi-
tions. With recent advances in biotechnology, new tech-
niques and tools are now available to isolate
components from food that have additional health
enhancing properties. Peptides are good candidates for
advanced clinical nutrition and supplements since they
are easily absorbed, and unlike many plant based com-
pounds, peptides are amino acids that can be eliminated
naturally by the body with less potential toxicity [1]. We
have isolated a peptide mixture from regular cow’s milk
that preliminary basic and clinical research indicates
may have some beneficial bioactive properties. The pur-
pose of this study was to: (1) characterize the molecular
mechanism of action; (2) assess the mixture’s safety in
healthy human subjects; and, (3) look for trends in
potential improvements that can be further explored in
future clinical trials in cancer patients.
Methods
Milk peptides
A milk peptide product AminoAct® (MP) was prepared
from normal cow’s milk and supplied by OncoNutrition
(Riverside, CA). A whey based peptide fraction was iso-
lated from pasteurized skim milk using proprietary
enzyme digestion and buffers. The final product was sup-
plied in an aqueous solution. Table 1 presents the nutri-
ent panel of the MP product examined in this report.
Basic Research Trials
Kinase IC50 Profiling
The inhibitory effects of the milk peptide mixture on
epidermal growth factor receptor (EGFR), vascular
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endothelial growth factor receptor 2 (VEGFR2), and insu-
lin receptor (IR) kinases were performed at Reaction Biol-
ogy Corporation (Malvern, PA). Briefly, specific kinase/
substrate pairs along with required cofactors were pre-
pared in reaction buffer; 20 mM Hepes pH 7.5, 10 mM
MgCl2, 1 mM EGTA (ethylene glycol tetraacetic acid),
0.02% Brij35, 0.02 mg/ml BSA (bovine serum albumin),
0.1 mM Na3VO4, 2 mM DTT (dithiothreitol), 1% DMSO
(dimethyl sulfoxide). Compounds were delivered into the
reaction, followed 20 minutes later by addition of a mix-
ture of ATP (Sigma, St. Louis MO) and 33P ATP (Perkin
Elmer, Waltham MA) to a final concentration of 10 μM.
Reactions were carried out at room temperature for 120
min, followed by spotting of the reactions onto P81 ion
exchange filter paper (Whatman Inc., Piscataway, NJ).
Unbound phosphate was removed by extensive washing of
filters in 0.75% Phosphoric acid. After subtraction of back-
ground derived from control reactions containing inactive
enzyme, kinase activity data was expressed as the percent
of remaining kinase activity in test samples compared to
vehicle (dimethyl sulfoxide) reactions. Ten concentrations
of milk peptides, with highest at 500 μM concentration,
were tested. IC50 values and curve fits were obtained using
Prism (GraphPad Software, La Jolla, California).
HT-29 Colon Cancer Cell Apoptosis Assay
HT-29 human colon cancer cells were grown in a 72-
well Terasaki plate until 80% confluent in McCoy’s 5A
medium, 10% FBS [2]. Vehicle, commercial hydrolyzed
whey protein (Thorne Research, Sandpoint, ID), and MP
mixture were added separately to each well in triplicates
for a final concentration of 0.68 μg/μl media. Pictures
were taken after 20 hr incubation.
C.elegans Lifespan Assay
The effects of the MP mixture on the lifespan of C. ele-
gans were performed at the University of Utah C.
elegans Research Core Facility (Salt Lake City, Utah)
using previously published methods [3]. Nematode
Growth Media (NGM) agar plates were prepared con-
taining either no peptides, or 20 μg/ml, 6.66 μg/ml, 0.66
μg/ml concentrations of the MP mixture. All plates
were seeded with E. Coli strain OP50. Experimental
plates were prepared in triplicate. Approximately 10 N2
(wild type strain) worms were cultured on four standard
agar plates or plates containing different dosages of MP.
In addition to using N2 worms on standard plates as
controls, other control plates included 40L4 mutant daf-
2 (el370) and 40 L4 daf-16(m26) larvae. The mean num-
ber of surviving worms for each day was recorded, and
the number of animals died on each day was calculated
and the values were used in log rank tests to examine
statistically significant differences. The results were
simultaneously evaluated using the c2 test and values
above 1.0 at a p-value of > 0.01 are considered statisti-
cally different when comparing longevity of N2 worms
on standard plates versus the test sample.
Clinical Safety Study
Subjects
The clinical trial was conducted as a placebo-controlled,
double-blind, parallel arm repeated measures study con-
ducted in a university setting. The protocol was
reviewed and approved by a human participants internal
review board (IRB) and written informed consent was
obtained from all patients prior to the initiation of
study. Subjects who were apparently healthy between
the ages of 35 - 60 years who had body mass index
(BMI) ranging between 27 and 40 with no known meta-
bolic disorders, history of milk allergies, and/or medical
conditions were eligible to participate in the study. Sub-
jects were matched according to gender, age, and body
mass and randomized to consume a placebo or the MP
mixture in a free living condition. Table 2 presents par-
ticipant demographics based on gender and group ran-
domization. Eighty-one subjects volunteered to
participate in this study with 73 completing the study.
Two males and six females did not complete the study.
Three cited time constraints with their schedules, two
missed multiple testing sessions, 2 did not give a specific
explanation and one participant who was in the supple-
ment group withdrew due to gastrointestinal distress
which could have been instigated by ingestion of the
milk or supplement.
Supplementation protocol
The MP mixture or a flavored water and glycerol pla-
cebo were administered in three escalating dosages
based on body weight over a six week period according
to the supplementation schedule described in Table 3.
Subjects took 1/2 dosage, mixed with 1/2 cup milk
immediately after breakfast and consumed the
Table 1 Nutrient content of milk peptide product
(per 100 ml)
Ingredient Amount
Calories (kcal) 12.1
Fat (kcal) 3.8
Fat (g) 0.4
Saturated Fat (g) 0.16
Sodium (mg) 476
Protein (g) 2
Calcium (mg) 112
Trans Fat (g) 0
Cholesterol (mg) 0
Sugars (g) 0
Carbohydrate (g) 0
Dietary Fiber (g) 0
Iron (mg) 0
Vitamins 0
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remaining 1/2 dosage with 1/2 cup milk immediately
after dinner. Supplementation compliance was moni-
tored by having participants return empty bottles of the
supplements as well as submitting a supplement log
documenting when supplements were ingested.
Clinical assessments
Subjects were evaluated at baseline, 3 weeks, and 6
weeks for general health markers. The independent vari-
able was MP supplementation. Dependent variables
included energy intake; body composition; resting heart
rate and blood pressure; a complete whole blood and
serum clinical chemistry panel; serum insulin and leptin;
measures of quality of life; and, symptoms and side
effects surveys.
Procedures
Participants recorded all food and fluid intake for four
days prior to each testing session which included three
weekdays and one weekend day. Dietary inventories
were reviewed by a registered dietitian and analyzed
using the ESHA Food Processor (Version 8.6) Nutri-
tional Analysis software (ESHA Research Inc., Salem,
OR). Height and body mass were determined using a
calibrated electronic scale (Cardinal Detecto Scale
Model 8430, Webb City, Missouri). Body composition
(excluding cranium) was assessed using a Hologic Dis-
covery W (Hologic Inc., Waltham, MA) dual energy x-
ray absorptiometer (DXA) equipped with APEX Soft-
ware (APEX Corporation Software, Pittsburg, PA). Rest-
ing heart rate was determined by palpitation of the
radial artery and blood pressure was assessed by auscul-
tation of the brachial artery using a mercurial sphygmo-
manometer using standard clinical procedures [4].
Whole blood samples were analyzed for complete
blood counts with platelet differentials using an Abbott
Cell Dyn 3500 (Abbott Laboratories, Abbott Park, IL)
automated hematology analyzer. Serum samples were
analyzed for a complete metabolic panel using a Dade
Behring Dimension RXL (Siemans AG, Munich, Ger-
many) automated clinical chemistry analyzer. Coefficient
of variation (range: 1.0 to 9.6%) for tests performed was
similar to previously published data for these tests [5].
Serum insulin and leptin were determined using com-
mercially available immuno-absorbent assay (ELISA) kits
(Diagnostic Systems Laboratories, Webster, TX) using a
Wallac Victor-1420 microplate reader (Perkin-Elmer Life
Sciences, Boston, MA) according to kit specifications.
Intra-assay and inter-assay coefficient of variation were
4%-7% for insulin and 2% - 8% for leptin. The homeos-
tasis model assessment for estimating insulin resistance
(HOMAIR) was calculated as the product of fasting glu-
cose times fasting insulin expressed in conventional
units divided by 405 [6]. Participants also completed the
SF-36 Quality of Life (QOL) inventory which has been
used to assess physical and mental components related
to QOL [7] as well as a symptom and side effect
questionnaire.
Statistical analysis
Related variables were grouped together and analyzed by
multivariate analysis of variance (MANOVA) with
repeated measures using PASW Statistics 18.0.2 software
(SPSS, Chicago, IL). Non-correlated variables were ana-
lyzed by univariate repeated measures analysis of variance
(ANOVA). Delta values were calculated and analyzed on
select variables by MANOVA for repeated measures to
assess changes from baseline values. Data were consid-
ered statistically significant when the probability of type I
error was 0.05 or less. If a significant group, treatment
and/or interaction alpha was observed, Tukey’s honestly
significant differences post-hoc analyses were performed.
Results
Basic Research Findings
A proprietary MP mixture was screened for tyrosine
kinase inhibitory activity. Notably, this particular peptide
mixture’s IC50 for EGFR, VEGFR2, and IR are 9.85 μM,
7.7 μM, and 6.18 μM respectively (Figure 1). In vitro,
the peptide mixture at 0.68 μg/μl causes cell death in
HT-29 human colon cancer cell line; whereas
Table 2 Participant descriptive data.
Variable Group Male Female Group × Gender
p-level
Age (yr) MP 47.0 ± 8 45.8 ± 8 0.11
P 45.2 ± 10 50.6 ± 8
Height (cm) MP 177 ± 11 163 ± 7 0.86
P 176 ± 6 163 ± 8
Weight (kg) MP 99.1 ± 13 82.5 ± 10 0.82
P 98.9 ± 13 83.8 ± 14
BMI (kg/m2) MP 31.7 ± 4 30.8 ± 3 0.75
P 31.8 ± 4 31.5 ± 4
Body Fat (%) MP 31.1 ± 7 40.0 ± 5 0.12
P 30.8 ± 4 43.6 ± 4
Data are means and ± standard deviations. MP = Milk Protein. P = Placebo.
Table 3 Supplementation dosing schedule (ml/d).
Weight Range Dosage for Week 1 & 2 Dosage for Week 3 & 4 Dosage for Week 5 & 6
< 100 kg 6 12 15
101 - 109 kg 9 15 18
> 110 kg 12 18 21
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commercial hydrolyzed whey powder did not cause cell
death (Figure 2). Hoechst dye staining showed the cell
death is accompanied with nuclear condensation and
DNA fragmentation, suggesting an apoptotic cell death,
and the apoptotic death is dose dependent (data not
shown). In vivo, C.elegans worms were used to test the
impact of MP on lifespan. Wild type L4 larval N2
worms were fed with or without the MP. In the group
that was fed with agar containing 20 μg/ml peptides, the
median survival where 50% worms were alive was Day
15, compared to Day 13. The last worm in the
controlled group died at Day 20, in contrast to Day 25
in the experimental group fed with agar containing milk
peptides (Figure 3). Statistical analysis of N2 standard
vs.MP fed worms showed a value of 6.1 (p = 0.014)
from c2 test, indicating a weak but significant statistical
significance. Lower concentrations of peptides did not
yield significant lifespan expansion (data not shown).
Clinical Safety Study Findings
No significant MANOVA or univariate ANOVA group
× time effects were seen in energy intake,
Figure 1 Determination of tyrosine kinase inhibitory properties of novel milk peptide mixture MP. The novel milk peptide mixture was
screened against a panel of kinases. Specifically, the IC50 for inhibition of epidermal growth factor receptor (EGFR), insulin receptor (IR), and
vascular epidermal growth factor receptor-2 (VEGFR2) were determined using a 10-point dose response radiolabeled assay.
Figure 2 Comparison of HT-29 human colon cancer cell death between commercially available whey peptides and the MP mixture.
HT-29 colon cancer cells were incubated with 0.68 μg/μl concentration of commercial hydrolyzed whey protein, MP peptides, and vehicle only
(control). Pictures were taken after 20 hours of incubation.
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macronutrient intake, or body composition between
groups. However, univariate ANOVA analysis revealed
small albeit significant differences in changes in fat
mass (P -0.23 ± 1.3; MP 0.44 ± 1.0 kg, p = 0.04) and
body fat percentage (P -0.57 ± 1.6; MP 0.2 ± 1.0%, p =
0.03) over time between groups. Resting heart rate
decreased to a greater degree in the P group (P -5.4 ±
7; MP -1 ± 7 beats/min, p = 0.01) with no differences
observed between groups in resting systolic or diastolic
blood pressure.
Whole blood analysis revealed no overall MANOVA
group × time effects (p = 0.60) among white blood cells,
neutrophils, lymphocytes, monocytes, eosinphils, baso-
phils, red blood cells, hemoglobin, hematocrit, mean cell
volume, or mean corpuscle hemoglobin count. A signifi-
cant univariate ANOVA quadratic interaction affect (p
= 0.05) was observed among groups in the neutrophil to
lymphocyte ratio (Figure 4). Serum analysis revealed no
overall MANOVA or univariate group × time effects
among triglycerides, total cholesterol, high density lipo-
proteins, low density lipoproteins, or uric acid; creatine
kinase, lactate dehydrogenase, aspartate amino transami-
nase, alanine amino transaminase, gamma glutamyl
transaminase, or alkaline phosphatase; and, blood urea
nitrogen (BUN), creatinine, BUN to creatinine ratio, cal-
cium, total protein, albumin, or total bilirubin. Figure 5
presents changes in hormonal responses observed dur-
ing the study. Although no statistically significant inter-
actions were observed, some potentially interesting
trends were observed which warrant further
investigation.
MANOVA analysis indicated that a group × time
trend (p = 0.06) was observed between groups in QOL
indices. As Figure 6 presents, univariate ANOVA analy-
sis revealed that participants in the MP group observed
a significantly greater increase (p = 0.01) in role physical
(i.e., ability to work and perform daily activities). No
Figure 3 MP fed C. elegans worms have a weak but significant
increase in life-span. – represents survival of wild-type (N2)
animals fed with standard agar; — represents survival of wild-type
animals fed with agar containing 20 μg/ml peptides. Control: n =
40, m = 13; Milk peptides (MP): n = 40, m = 15 (P = 0.0136). n
represents the number of animals observed in each experiment. m
represents the median adult life span.
Figure 4 Neutrophil to lymphocyte ratio values observed for
the placebo (P) and milk protein (MP) groups over time.
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Figure 5 Change in hormonal responses from baseline
observed for the placebo (P) and milk protein (MP) groups.
HOMAIR represents homeostatic model assessment of insulin
resistance.
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significant side effects were observed for frequency of
dizziness, racing heart rate, skip heart beats, shortness
of breath, nervousness, or blurred vision. Moreover, no
subject was medically removed from the study or was
referred for medical consultation.
Discussion
Milk represents a unique source of nutrients and biolo-
gically active components that act in synergy, as well as
independently. Emerging evidence indicates that the
protein component of milk represents a variety of biolo-
gically active proteins/peptides that function as anti-
hypertensive agents, antimicrobial factors, food intake
modifiers and immune regulatory factors [8,9]. Interest-
ingly, many bioactive peptides are inactive within their
parent milk proteins, and upon release during digestion
or food processing, they may act as regulatory com-
pounds with hormone-like activity [10,11]. Additionally,
there are increasing studies showing that bioactive milk
peptides can be absorbed intact from the intestinal
lumen into the blood circulation - these may thus serve
as novel functional food ingredients or pharmaceutical
agents [12-15].
Using a proprietary enzyme digestion and buffer iso-
lation method, we purified a group of peptides from
the whey fraction of regular cow’s milk and screened
against a panel of kinases. In particular, this milk pep-
tide mixture shows inhibitory effects against EGFR,
VEGFR2, and IR. EGFR is often overexpressed in non-
small cell lung cancer (NSCLC) and a variety of
common solid tumors. EGFR signaling is generally
associated with cancer invasion, metastasis, che-
motherapy resistance, and poor prognosis [16,17]. It
has also been reported that inhibition of EGFR may
lead to apoptosis in certain cancer cell lines [18].
Gefitinib (Iressa®, AstraZeneca plc, London, UK) and
Erlotinib (Tarceva®, Genentech, Inc., San Francisco,
CA) are examples of anti-cancer drugs targeting
EGFR-TK. Interestingly, MP mixture is also able to
cause significant cell death in HT29 colon cancer
cells, whereas neither commercially available hydro-
lyzed whey proteins nor whole milk proteins exhibited
the same property. This may be because most com-
mercial hydrolyzed whey proteins contained too small
amount of bioactive peptides or the process of spray
drying deactivated the activity.
This novel MP mixture also inhibits insulin receptor
signaling. Interestingly, mutations in daf-2, a gene that
encodes an insulin-like receptor in C. elegans worm,
have been shown to double the lifespan of the worms
[19]. The gene is known to regulate reproductive devel-
opment, ageing, resistance to oxidative stress, thermoto-
lerance, resistance to hypoxia and also resistance to
bacterial pathogens [20]. Therefore, we next tested this
unique MP mixture effect on the lifespan of C. elegans
worms. Statistical analysis of the result suggested that
N2 worms fed with agar containing 20 μg/ml concentra-
tion of milk peptides increased the median lifespan by
15.4% (p = 0.014). Based on these data, we hypothesize
that this milk peptide mixture may be a novel supple-
ment ingredient for anti-aging and cancer preventive
regimen.
Since MP has multi-kinase inhibitory activity in the
micromolar range, we first conducted toxicology studies
to measure the safety of these peptides. An acute and a
28-day sub-acute toxicology study showed no apparent
adverse effects in rodents following oral administration
of the peptides. Encouraged by the results, we con-
ducted an 80 subject, double blind, placebo controlled
study in healthy volunteers. The main purpose was to
assess the safety of the milk peptides at three escalating
dosages.
The clinical analyses showed that the MP mixture did
not cause significant side effects in healthy human sub-
jects. All blood and hormonal markers remained in nor-
mal ranges. There was a mean trend toward improving
insulin sensitivity as assessed using HOMAIR that war-
rants additional study. This could potentially have bene-
ficial effects for individuals with insulin resistance.
However, these changes were not significant due to the
large variability in responses observed. Additional study
evaluating the effects of these milk peptides on glucose
tolerance in individuals with and without insulin resis-
tance would help elucidate this potential effect.
Figure 6 Comparison between placebo and MP group in role
physical measure of quality of life.
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Another encouraging trend was the lowering of neu-
trophil to lymphocyte ratio (NLR). The neutrophil-lym-
phocyte ratio is a general marker of immunity and
inflammatory status. Research has shown that elevated
NLR to be a prognostic indicator of poor chemotherapy
outcomes in advanced colorectal cancer and poor survi-
val after colorectal liver metastases [21-23]. The poten-
tial impact of MP supplementation on lowering NLR
could be used as a clinical nutritional intervention for
these categories of cancer patients. In addition, these
peptides have been shown to have in vitro anti-EGFR
and VEGFR2 activity. EGFR is commonly elevated in
many advanced cancers, and VEGFR2 is considered one
of the key regulators of tumor-induced angiogenesis
[24,25]. Together, this novel milk peptide mixture’s anti-
cancer and inflammatory reducing properties may be a
safe, effective supplement to help cancer patients under-
going chemotherapy to obtain better clinical outcome.
In summary, preliminary experiments suggest that
there may be some potentially beneficial applications of
this novel MP mixture and that six weeks of human
consumption appears to be safe. The limitation of this
first clinical study is that the human subjects were
healthy individuals. Additional clinical studies are cur-
rently underway to further elucidate the milk peptides’
impact on the progression of cancer and quality of life
in cancer patients.
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